

March 27, 2026

Symbio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director,  
President and Chief Executive Officer

**Notice Regarding the Acceleration of Exercise of the 66th Stock Acquisition Rights  
Issued through Third-Party Allotment**

Symbio Pharmaceuticals Limited (the “Company”) hereby announces that, with respect to the 66th Stock Acquisition Rights issued on August 12, 2025 to EVO FUND (the “Stock Acquisition Rights”), it has resolved, as of today, to instruct the allottee, EVO FUND, to accelerate the exercise of the Stock Acquisition Rights in accordance with the purchase agreement entered into with EVO FUND.

As conditions for such acceleration of exercise, the Company must not hold any undisclosed insider information, and no outstanding 65th Stock Acquisition Rights may remain. The Company confirms that these conditions have been satisfied as of the date of the instruction to accelerate the exercise.

1. Name of Stock Acquisition Rights	Symbio Pharmaceuticals Limited’s 66th Stock Acquisition Rights
2. Number of Stock Acquisition Rights	200,000 rights (20,000,000 shares)
3. Date of Instruction for Acceleration of Exercise	March 27, 2026
4. Exercise Commencement Date	March 30, 2026

For details regarding the issuance of the Stock Acquisition Rights, please refer to the “Notice Regarding the Issuance of the 65th to 67th Stock Acquisition Rights (with Exercise Price Adjustment Clauses) through Third-Party Allotment and the Execution of a Purchase Agreement (Commit Issue) for the 1st Unsecured Straight Bonds and Stock Acquisition Rights,” dated July 22, 2025.